Henry Schein, Inc. (Nasdaq: HSIC), the global leader in healthcare solutions for office-based dental and medical practitioners, has announced a landmark $250 million strategic investment by funds affiliated with KKR, a premier global investment firm. This pivotal capital infusion grants KKR approximately 12% ownership of Henry Schein’s common shares, marking a strategic partnership that is poised to accelerate Henry Schein’s long-term growth trajectory. (Source: https://sec.gov/Archives/edgar/data/1000228/000119312525121679/d919434dex991.htm)
This investment comes as part of Henry Schein’s bold strategic initiative, BOLD+1, aimed at driving sustainable profitability and operational excellence in a complex healthcare market environment. KKR’s entry onto the shareholder register is complemented by the appointments of William K. “Dan” Daniel, an esteemed Executive Advisor to KKR and former Executive Vice President at Danaher Corporation, and Max Lin, KKR Partner and leader of its Health Care industry team in the Americas, to the Henry Schein Board of Directors. Their combined decades of experience in healthcare, operations, and strategic growth innovation bring robust expertise critical to Henry Schein’s expansion.
Financially, Henry Schein reported fiscal year 2024 revenue of \(12.67 billion, with net income of \)390 million, reflecting its significant scale and stable profitability. Since going public in 1995, the company has achieved a compound annual growth rate (CAGR) of approximately 11.2%, highlighting consistent expansion supported by a broad portfolio of over 300 healthcare solutions. (Fiscal Year Ending December 28, 2024)
At the recent Q1 2025 earnings call, Henry Schein’s management emphasized the constructive collaboration with KKR, focusing on value creation through strategic initiatives under the BOLD+1 growth plan. Max Lin and Dan Daniel’s presence on the board is expected to further amplify these efforts, enhancing shareholder value via operational efficiencies and innovative healthcare delivery models.
Henry Schein’s expansive network includes approximately 25,000 team members and serves over 1 million customers globally, with operations in 33 countries. Their centralized, automated distribution system stocks more than 300,000 branded and proprietary products, ensuring efficient supply chain management and product availability to diverse care sites including dental labs and government health clinics.
KKR’s strategic involvement, with its deep expertise in private equity, credit, insurance, and healthcare sectors, promises to support Henry Schein in navigating economic uncertainties, evolving government efficiency measures, and supply chain challenges, which are prevailing headwinds in today’s global healthcare market.
In summary, this strategic investment by KKR not only strengthens Henry Schein’s capital base but also enriches its governance and strategic oversight. The partnership is set to propel Henry Schein’s ambitious BOLD+1 strategy forward, promising enhanced value for stakeholders amidst a dynamic healthcare landscape.
For comprehensive details, review the original 8-K filing here: https://sec.gov/Archives/edgar/data/1000228/000119312525121679/d919434dex991.htm
Tags: HSIC, HenrySchein, FY2024, HealthcareInvestments, StrategicPartnership, KKRInvestment